Browsing by Author "Gul, Cihan"

Now showing 1 - 2 of 2

The Effect of Resveratrol Treatment on Heart Rate and Qt Values in Rats With Chronic Fluorosis
(Parlar Scientific Publications (p S P), 2022) Bulduk, Bahattin; Oto, Gokhan; Ozdemir, Hulya; Gunbatar, Nizamettin; Kocak, Yilmaz; Gul, Cihan; Elasan, Sadi
With this study, it was investigated how the impact of sodium fluoride (NaF) exposure on the cardiac conduction system would be treated with resveratrol. A total of 8 rats, 4 female and 4 male, weighing 200-300 grams, were used in each group. The first group was separated as the control group. The second group was determined as the group given 10 melt/day NaF, the third group as the group given 50 mg/It/day resveratrol, and the fourth group as the group given 10 mg/It/day NaF + 50 mg/It/day resveratrol. In the study conducted for 12 weeks, resveratrol and NaF were mixed into the drinking water of rats. When the study was finished after 4 months, the rats were anesthetized. They were placed in the right lateral position for the recording of ECGs. ECG samples were evaluated in II. derivation. Heart rate numbers were found high and QT values were found low in the groups that were administered only NaF. The heart rate and QT values of the groups administered with resveratrol alone or in combination with NaF showed parallelism with the control group.
Possible Relationships Between Placenta and Serum Asprosin Levels and Pregnancy and Spontaneous Preterm Births
(BMC, 2025) Gul, Cihan; Uckan, Kazim; Cibuk, Salih
ObjectiveAsprosin, a newly characterised adipokine, has been implicated in several physiological and pathological pathways. This study aimed to explore the association between serum and placental asprosin concentrations and the occurrence of preterm births by evaluating their potential as predictive biomarkers.MethodsA total of 75 participants were enrolled in this cross-sectional study and categorised into four groups - early preterm (delivery before 34 weeks, n = 15), late preterm (34-37 weeks, n = 15), term delivery (37-42 weeks, n = 30) and nonpregnant controls (n = 15). Serum samples were collected from all individuals, and placental tissues were obtained postdelivery from pregnant participants. Asprosin concentrations were quantified using ELISA, and correlation analyses were conducted to determine associations with clinical variables.ResultsSignificantly elevated asprosin levels were detected in both the serum and placental samples of women with preterm births compared to term deliveries (p = 0.008 for placental samples, p = 0.001 for serum samples). The highest levels were noted in the early preterm group (placental: 18.88 +/- 2.12 ng/ml; serum: 19.04 +/- 3.15 ng/ml). Strong inverse correlations were identified between asprosin levels and gestational age (placental: r = -0.647, p = 0.01; serum: r = -0.716, p = 0.01) and between serum asprosin and neonatal birth weight (r = -0.683, p = 0.01). The ROC analysis indicated cutoff values of 16.58 ng/ml (placenta) and 15.22 ng/ml (serum) as potential thresholds for preterm birth prediction.ConclusionIncreased maternal serum and placental asprosin levels are linked to preterm birth, demonstrating inverse associations with gestational duration and infant birth weight. These results suggest a potential role for asprosin as a predictive biomarker for preterm birth, warranting further mechanistic investigation.